Clinical efficacy of Chushi Pixuan Ointment in the topical treatment of tinea pedis

Not Applicable

Recruiting

• Conditions: tinea pedis; 1F28

• Registration Number: ITMCTR2024000013
• Lead Sponsor: Department of Dermatology, Guangdong Provincial Hospital of Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 4 March 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1 Age: 18-65 years old;
2 Meet the diagnostic criteria;
3 Those who can complete the test as required and sign the informed consent;

Exclusion Criteria

1 Those who have received systemic antifungal drugs in the last 3 months or topical antifungal drugs in the last 2 weeks;
2 Those who have received long-term treatment with corticosteroids and immunosuppressants;
3 Women who are breastfeeding and pregnant;
4 Those who have received radiotherapy, anti-viral, anti-bacterial, anti-helminthic treatment within the last 2 weeks;
5 Those who are unable to accept and complete the survey as required;
6 Those with co-morbid nail fungal disease, co-morbid bacterial infections such as dengue;
7 Those who have significant abnormalities in the examination of various systems such as blood, liver, kidney and heart; those who have combined serious primary diseases such as cardiovascular, cerebrovascular, hepatic, renal, neurological and haematopoietic systems; and those who are suffering from psychiatric diseases, malignant tumours, diabetes mellitus and autoimmune diseases;
8 Patients who are themselves investigators directly involved in the work of this study;
9 Patients who are allergic to therapeutic drugs;
10 Those with negative laboratory tests for fungi.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Efficacy index;Mycological examination;

Secondary Outcome Measures

Name	Time	Method
Evaluation of recurrence (including recurrence or reinfection);Mycological efficacy evaluation;Quality of life score;Evaluation of clinical signs and symptoms;